HIV virologic response and baseline genotypic resistance in a long-acting cabotegravir/rilpivirine initiation program

A cautionary note on entry and exit strategies with long-acting cabotegravir and rilpivirine

“…Obtaining drug resistance data from HIV DNA can also be a barrier as most laboratories have long implemented RNA, but not DNA, analysis. However, we encourage HIV specialists not to skip this baseline analysis, as it may indeed detect RPV resistance [7,20] and avoid the risk of emergent resistance at failure of LA CAB-RPV therapy.…”